在患有复发性复发性多发性硬化症的患者中,Ocrelizumab对多发性硬化症的影响的多奥米特征表征
Sergey A Kornilov1, Nathan D Price2, Richard Gelinas1
1Institute for Systems Biology, WA, USA.
Journal of the neurological sciences
|November 19, 2024
概括
对复发性缓解性多发性硬化症 (RRMS) 的ocrelizumab治疗迅速耗尽B细胞和相关蛋白质. 这种免疫调节涉及代谢重编程和B细胞激活因子 (BAFF) 的补偿性增加.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 代谢学 代谢学 代谢学
背景情况:
- 复发性复发性多发性硬化症 (RRMS) 是一种自身免疫性疾病,其特征是免疫系统对中枢神经系统的攻击.
- 奥克雷利祖马布是一种向治疗,消耗表达CD20的B细胞,这是MS治疗的关键机制.
- 了解由ocrelizumab诱导的全身分子变化对于评估其超出B细胞枯竭的治疗效果至关重要.
研究的目的:
- 为了研究与ocrelizumab治疗的RRMS患者的血蛋白质组,代谢组和脂质组的纵向变化.
- 为了识别与ocrelizumab治疗相关的早期和晚期分子事件.
- 探索基线疾病负担 (MRI病变负载) 和生物标志物反应之间的关系.
主要方法:
- 从14名RRMS患者的血样本在基线,6个月和12个月后进行了分析.
- 通过蛋白质组,代谢组和脂质组测定量化了超过4000个循环生物标志物.
- 数字细胞测量被用来评估免疫细胞种群.
主要成果:
- 在6个月后观察到B细胞标记物和细胞因子的早期消耗,以及神经轴损伤和特定脂质 (胺,溶性脂) 的减少标记物.
- 在B细胞耗尽后,B细胞激活因子 (BAFF) 的显著增加被注意到.
- 在12个月后,各种信号和代谢途径的上调发生,在基线病变负载较高的患者中具有不同的轨迹.
- 数字细胞测量表明骨髓状细胞的增加和一种亲炎性T细胞子集.
结论:
- 在RRMS中,ocrelizumab的治疗作用涉及到B细胞溶解之外的更广泛的代谢重编程.
- 观察到的BAFF的增加可能代表B细胞复合的补偿机制.
- 系统生物标志物变化与疾病活性和治疗反应相关,突出显示了免疫和代谢变化的复杂相互作用.
相关概念视频
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...